![](/images/graphics-bg.png)
Lobaplatin-based regimens outperform cisplatin for metastatic breast cancer after anthracyclines and taxanes treatment
Joint Authors
Wang, Han
Zhang, Qingyuan
Lu, Lu
Li, Zhenzhi
Xu, Lei
Li, Xiaojiao
Source
Saudi Journal of Biological Sciences
Issue
Vol. 25, Issue 5 (31 Jul. 2018), pp.909-916, 8 p.
Publisher
Publication Date
2018-07-31
Country of Publication
Saudi Arabia
No. of Pages
8
Main Subjects
Abstract EN
The goal of this study was to assess the antitumor efficacy and safety of lobaplatin-based regimens as the second line of treatment in patients with metastatic breast cancer (MBC) resistant to anthracyclines and taxanes, compared with that of cisplatin-based regimens.
During August 2012 to April 2015, 87 patients who received lobaplatin-based regimens or cisplatin-based regimens were included.
Medical records of the patients noted that lobaplatin (30 mg/m2) or cisplatin (25 mg/m2), combined with another chemotherapeutic agent such as Gemcitabine (1000 mg/m2) or Vinorelbine (25 mg/m2), was intravenously given to the patients on a basis of twenty-one days as one treatment cycle.
All the patients were followed until August 2017.
The endpoint of this study was progression-free survival (PFS), overall survival (OS), and estimated objective response rate (RR).
Safety and drug tolerability data were also obtained.
Lobaplatin-based regimens prolonged PFS compared to cisplatin-based regimens (median 13.2 vs 4.7 months, hazard ratio = 0.37, 95% confidence intervals: 0.21–0.67, P = .0007), while OS was not significantly different between the two groups (hazard ratio = 0.72, 95% confidence intervals: 0.40–1.30, P = .2767), as was objective RR (37.8% vs 33.4%, x2 = 0.19, P = .6653).
Nausea/vomiting and renal injury were more frequent with cisplatin-based regimens.
Our results show that lobaplatinbased regimens are superior to cisplatin in terms of efficacy and are better tolerated.
American Psychological Association (APA)
Xu, Lei& Wang, Han& Li, Zhenzhi& Lu, Lu& Li, Xiaojiao& Zhang, Qingyuan…[et al.]. 2018. Lobaplatin-based regimens outperform cisplatin for metastatic breast cancer after anthracyclines and taxanes treatment. Saudi Journal of Biological Sciences،Vol. 25, no. 5, pp.909-916.
https://search.emarefa.net/detail/BIM-838768
Modern Language Association (MLA)
Xu, Lei…[et al.]. Lobaplatin-based regimens outperform cisplatin for metastatic breast cancer after anthracyclines and taxanes treatment. Saudi Journal of Biological Sciences Vol. 25, no. 5 (Jul. 2018), pp.909-916.
https://search.emarefa.net/detail/BIM-838768
American Medical Association (AMA)
Xu, Lei& Wang, Han& Li, Zhenzhi& Lu, Lu& Li, Xiaojiao& Zhang, Qingyuan…[et al.]. Lobaplatin-based regimens outperform cisplatin for metastatic breast cancer after anthracyclines and taxanes treatment. Saudi Journal of Biological Sciences. 2018. Vol. 25, no. 5, pp.909-916.
https://search.emarefa.net/detail/BIM-838768
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 915-916
Record ID
BIM-838768